Cardiex (ASX:CDX) share price rises 6% on new patent

The Cardiex share price closed higher today as it was announced the company has recieved a new patent. We take a look at the details.

heart shaped balloons flying in the air representing Cardiex share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cardiex Ltd (ASX: CDX) share price was rising today as the company announced it had received a new blood pressure patent. The Cardiex share price closed today's trading 6.12% higher at 5.2 cents.

What Cardiex does

Cardiex is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders.

The company's ATCOR division develops medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented technology.

Under the ATCOR.X brand, the company also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. The company's digital platform, ArtyNet, is a connected software-as-a-service (SaaS) ecosystem providing physicians with a complete telehealth solution for remotely managing patients' health (2021 launch).

Cardiex gets blood pressure patent

It was announced this afternoon that Cardiex's subsidiary, ATCOR, has been granted a new patent by the European Patent Office. The patent is in relation to the intellectual property (IP) for the Company's proprietary SphygmoCor technology used in cuff-based blood pressure devices.

The patent protects the company's IP in relation to the measurement of a whole central blood pressure waveform with cardiovascular features using a brachial cuff. It also covers non-invasively estimating the heart's pressure with features related to cardiac function and arterial properties using a conventional blood pressure cuff inflated to low pressure.

CEO and Managing Director of Cardiex, Craig Cooper, commented:

We are very pleased to be granted this new patent to protect our IP in Europe. Of great significance is the findings of the examining officers from the EPO which were similar to the findings we received from examiners in the US in 2016 – that there are substantial differences in respect of any other existing patents – further demonstrating and validating the uniqueness of our technology.

What now for the Cardiex share price?

This represents a significant step forward for the company in protecting its IP in Europe. Its SphygmoCor technology has over 4500 installations worldwide. Furthermore, the technology is used by major pharmaceutical companies and research institutions such as GlaxoSmithKline plc (NYSE: GSK), AstraZeneca plc (NYSE: AZN) and Bayer AG (ETR: BAYN).

The Cardiex share price is currently trading 73.33% higher so far this year.

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man stands with his arms folded in front of banks of unused poker machines in a darkened gaming room.
Share Market News

Broker tipping 50% upside for this consumer discretionary company

This ASX 200 company could be set for a rebound

Read more »

a smiling picture of legendary US investment guru Warren Buffett.
Opinions

Would Warren Buffett buy Soul Patts shares?

Soul Patts is an impressive business. But would it appeal to one of the world’s greatest investors?

Read more »

Businessman cheering at desk with arms in the air
Technology Shares

Xero share price halted amid $3.9b game-changing US acquisition

The market darling is aiming to accelerate growth in the US with this major deal.

Read more »

Share Market News

Why these strong ASX dividend shares could be top buys for income investors

Analysts are saying good things about these income options.

Read more »

Happy man working on his laptop.
Share Market News

5 things to watch on the ASX 200 on Wednesday

Another positive session is expected for Aussie investors today.

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors enjoyed a strong recovery day this Tuesday.

Read more »

Person pointing finger on on an increasing graph which represents a rising share price.
Broker Notes

These ASX shares could rise 20% to 30%

Big returns could be on the cards for buyers of these shares according to analysts.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Broker Notes

All about the momentum: Which ASX 200 stocks does Macquarie currently favour?

These stocks have strong positive momentum.

Read more »